|
"楊志新"的相關文件
顯示項目 116-140 / 209 (共9頁)
<< < 1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2010 |
Chemotherapy Response in East Asian Non-Small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors
|
林家齊; 徐心馨; 孫家棟; 施金元; 林宗哲; 余忠仁; 楊志新; LIN, CHIA-CHI; HSU, HSIN-HSIN; SHUN, CHIA-TUNG; SHIH, JIN-YUAN; LIN, ZONG-ZHE; YU, CHONG-JEN; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2010 |
Correlation of F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value and Egfr Mutations in Advanced Lung Adenocarcinoma
|
黃俊達; 顏若芳; 鄭媚方; 衛品妃; 蔡怡汝; 蔡孟峰; 施金元; 楊志新; 楊泮池; HUANG, CHUN-TA; YEN, RUOH-FANG; CHENG, MEI-FANG; WEI, PIN-FEI; TSAI, YI-JU; TSAI, MENG-FENG; SHIH, JIN-YUAN; YANG, CHIH-HSIN; YANG, PAN-CHYR |
| 國立臺灣大學 |
2010 |
Influence of First-Line Chemotherapy and Egfr Mutations on Second-Line Gefitinib in Advanced Non-Small Cell Lung Cancer
|
巫震宇; 余忠仁; 施金元; 楊志新; 楊泮池; WU, JENN-YU; YU, CHONG-JEN; SHIH, JIN-YUAN; YANG, CHIH-HSIN; YANG, PAN-CHYR |
| 國立臺灣大學 |
2010 |
Second-Line Treatments after First-Line Gefitinib Therapy in Advanced Nonsmall Cell Lung Cancer
|
巫震宇; 施金元; 楊志新; 陳冠宇; 何肇基; 余忠仁; 楊泮池; WU, JENN-YU; SHIH, JIN-YUAN; YANG, CHIH-HSIN; CHEN, KUAN-YU; HO, CHAO-CHI; YU, CHONG-JEN; YANG, PAN-CHYR |
| 國立臺灣大學 |
2010 |
Use of Cetuximab after Failure of Gefitinib in Patients with Advanced Non- Small-Cell Lung Cancer
|
巫震宇; 楊志新; 余忠仁; 楊泮池; 施金元; WU, JENN-YU; YANG, CHIH-HSIN; YU, CHONG-JEN; SHIH, JIN-YUAN; YANG, PAN-CHYR |
| 國立臺灣大學 |
2010 |
Quality of Life (Qol) in a Randomized Phase Iii First-Line Study of Gefitinib (G) Vs Carboplatin/Paclitaxel (Cp) in Clinically Selected Asian Patients (Pts) with Advanced Nsclc (Ipass)
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2010 |
Final Overall Survival Os Results from a Phase Iii, Randomised, Open-Label , First-Line Study of Gefitinib G V Carboplatin/Paclitaxel C/P in Clinically Selected Patients with Advanced Non-Small Cell Lung Cancer Nsclc in Asia Ipass
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2010 |
Phase 2 Results of Xl184 in a Cohort of Patients Pts with Advanced Non- Small Cell Lung Cancer Nsclc
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Bibw 2992, a Novel Irreversible Egfr/Her2 Tyrosine Kinase Inhibitor, in Chemonaive Patients with Adenocarcinoma of the Lung and Activating Egfr Mutations
|
楊志新; 施金元; 蘇五洲; 夏德椿; YANG, CHIH-HSIN; SHIH, JIN-YUAN; SU, WU- CHOU; HSIA, TE-CHUN |
| 國立臺灣大學 |
2009 |
Clinical Outcomes of Patients with Epidermal Growth Factor Receptor (Egfr ) Mutations (Mut) in Ipass (Iressatm Pan Asia Study)
|
趙祖怡; 楊志新; CHAO, TSU-YI; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Vandetanib Plus Pernetrexed Versus Pemetrexed as 2nd-Line Therapy in Patients with Advanced Nsclc: A Randomized, Double-Blind Phase Iii Trial ( Zeal)
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
An Open-Label Single-Arm Phase Iv Study of Pemetrexed in Taiwanese Patients with Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy
|
張基晟; 蔡俊明; 夏德椿; 楊志新; CHANG, GEE-CHEN; TSAI, CHUN-MING; HSIA, TE-CHUN; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Vandetanib Plus Pemetrexed Vs Pemetrexed as 2nd-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (Nsclc); a Randomized, Double- Blind Phase Iii Trial
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Melatonin Inhibits Arsenite-Induced Peripheral Neurotoxicity
|
林滿玉; 范素芬; 趙珮玲; 楊志新; LIN, A. MAAN-YUH; FANG, SU-FEN; CHAO, PEI -LING; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
First-Line Systemic Treatment of Advanced Stage Non-Small-Cell Lung Cancer in Asia: Consensus Statement from the Asian Oncology Summit 2009
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Comparison of Epidermal Growth Factor Receptor Mutations between Primary and Corresponding Metastatic Tumors in Tyrosine Kinase Inhibitor-Naive Non -Small-Cell Lung Cancer
|
高劍虹; 張逸良; 蔡孟峰; 吳振都; 余忠仁; 楊志新; 李元麒; 楊泮池; 施金元; GOW, CHIEN-HUNG; CHANG, YIH-LEONG; TSAI, MENG-FENG; WU, CHEN-TU; YU, CHONG-JEN; YANG, CHIH-HSIN; LEE, YUNG-CHIE; YANG, PAN-CHYR; SHIH, JIN-YUAN |
| 國立臺灣大學 |
2009 |
Egfr Intron 1 Dinucleotide Repeat Polymorphism Is Associated with the Occurrence of Skin Rash with Gefitinib Treatment
|
黃敬倫; 楊志新; 葉坤輝; 胡賦强; 陳冠宇; 施金元; 林宗哲; 余忠仁; 鄭安理; 楊泮池; HUANG, CHING-LUN; YANG, CHIH-HSIN; YEH, KUN-HUEI; HU, FU-CHANG; CHEN, KUAN-YU; SHIH, JIN-YUAN; LIN, ZONG-ZHE; YU, CHONG-JEN; CHENG, ANN-LII; YANG, PAN-CHYR |
| 國立臺灣大學 |
2009 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Elderly or Poor Performance Status Patients with Advanced Non-Small Cell Lung Cancer
|
林家齊; 楊志新; LIN, CHIA-CHI; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital
|
林家齊; 楊志新; 鄭安理; 陳榮楷; 何弘能; LIN, CHIA-CHI; YANG, CHIH-HSIN; CHENG, ANN-LII; CHAN, WING-KAI; HO, HONG-NERNG |
| 國立臺灣大學 |
2009 |
Quality of Life in Advanced Non-Small Cell Lung Cancer Patients Receiving First-Line Gefitinib Monotherapy
|
邵幼雲; 林宗哲; 胡賦强; 余忠仁; 施金元; 胡文郁; 張逸良; 鄭安理; 楊泮池; 楊志新; SHAO, YU-YUN; LIN, ZONG-ZHE; HU, FU-CHANG; YU, CHONG-JEN; SHIH, JIN-YUAN; HU, WEN-YU; CHANG, YIH-LEONG; CHENG, ANN-LII; YANG, PAN-CHYR; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
A Phase Ii Study of Bibw 2992, a Novel Irreversible Dual Egfr and Her2 Tyrosine Kinase Inhibitor (Tki), in Patients with Adenocarcinoma of the Lung and Activating Egfr Mutations after Failure of One Line of Chemotherapy (Lux-Lung 2)
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Biomarker Analyses from a Phase Iii, Randomized, Open-Label, First-Line Study of Gefitinib (G) Versus Carboplatin/Paclitaxel (C/P) in Clinically Selected Patients (Pts) with Advanced Non-Small Cell Lung Cancer (Nsclc) in Asia (Ipass)
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Efficacy of Pemetrexed-Cisplatin (Pc) in East Asian Patients (Pts): Subgroup Analysis of a Phase Iii Study Comparing Pc Versus Gemcitabine- Cisplatin (Gc) in First-Line Treatment of Advanced Non-Small Cell Lung Cancer (Nsclc)
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Phase Iib/Iii Double-Blind Randomized Trial of Bibw 2992, an Irreversible, Dual Inhibitor of Egfr and Her2 Plus Best Supportive Care (Bsc) Versus Placebo Plus Bsc in Patients with Nsclc Failing 1-2 Lines of Chemotherapy (Ct) and Erlotinib or Gefitinib (Lu
|
楊志新; YANG, CHIH-HSIN |
顯示項目 116-140 / 209 (共9頁)
<< < 1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
|
